Rituxan cancer drug extends lives in combo with chemo, Roche says

12/8/2004 | Reuters

Roche announced its MabThera cancer drug can be combined with chemotherapy to extend the lives of patients with indolent non-Hodgkin's Lymphoma. New data revealed by the Swiss firm indicated Rituxan, marketed in the U.S. by Roche's Genentech unit and Biogen Idec, prolonged lives for at least two years after treatment.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD